Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491792 | 0.85 | KMT2A (0.46) | FOLH1ALDH1A1HTTHMGB1KDM4E | |
| SCHEMBL29062 | 0.84 | FOLH1 (0.66) | FOLH1ALDH1A1ALOX15HTTHMGB1 | |
| SCHEMBL9627316 | 0.84 | MAPT (0.50) | FOLH1ALDH1A1TSHRLMNAGAA | |
| SCHEMBL30365583 | 0.83 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15HTTHMGB1 | |
| SCHEMBL70392 | 0.83 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15HTTHMGB1 | |
| SCHEMBL9321175 | 0.83 | MTNR1A (0.47) | ALDH1A1KDM4ELMNASMN1; SMN2MTNR1A | |
| SCHEMBL2491789 | 0.83 | FOLH1 (0.46) | FOLH1ALDH1A1HTTHMGB1KDM4E | |
| SCHEMBL27568253 | 0.82 | FOLH1 (0.63) | FOLH1ALDH1A1ALOX15HTTHMGB1 | |
| SCHEMBL4768892 | 0.81 | ALDH1A1 (0.67) | FOLH1ALDH1A1ALOX15HTTHMGB1 | |
| SCHEMBL3571210 | 0.80 | ALDH1A1 (0.45) | FOLH1ALDH1A1HTTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020091142-A1 | Alpha4beta1 and alpha4beta7 integrin inhibitors | COOKE NIGEL GRAHAM (US) | 2002-07-11 | — | — | US | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| WO-2001068586-A2 | α4β1 AND α4β7 INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2001-09-20 | — | — | WO | disclosed |
| CN-1056602-C | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-09-20 | — | — | CN | disclosed |
| CN-1197450-A | Esters and amides as phospholipase A2 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-28 | — | — | CN | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091142-A1 | Alpha4beta1 and alpha4beta7 integrin inhibitors | ITGB1, ITGB4, ITGB7 | FOLH1 4398/4885ALDH1A1 152/4885ALOX15 1984/4885 |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | FOLH1 3723/4885ALDH1A1 800/4885ALOX15 53/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | FOLH1 3878/4885ALDH1A1 700/4885ALOX15 55/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | FOLH1 3522/4885ALDH1A1 737/4885ALOX15 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.